Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical, Inc. is trading at $23.80, down 0.96% on the session. The 50 day average sits at $23.30 and the 200 day at $33.24, which puts the stock in a downtrend. RSI is at 56.9, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $22.15 with resistance near $23.85, so that band frames the current range. Average daily movement is roughly $0.84, or about 3.5% of the share price, which is what any stop placement has to allow for. The overall health score of 51 out of 100 combines a trend score of 20, momentum of 83 and a risk score of 57.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.